Humans ; Gingival Recession/surgery* ; Gingivoplasty/methods* ; Connective Tissue/transplantation* ; Treatment Outcome ; Gingiva/transplantation* ; Tooth Root

PURPOSE: In advanced case of periodontitis, surgical treatment without bone contouring may result in residual pockets inaccessible to proper cleaning during post-treatment maintenance. This problem can be avoided or reduced by applying guided tissue regeneration. MATERIALS AND METHODS: All of 3 patients had deep periodontal pocket depth and bleeding on probing, and radiograph revealed osseous defect, so we planned guided tissue regeneration using resorbable membrane with or without xenograft. RESULT: 6 months later, periodontal pocket depth and bleeding on probing was improved and gingiva was stable. CONCLUSION: Guided tissue regeneration using resorbable membrane with or without xenograft in osseous defect is predictable.
Gingiva ; Guided Tissue Regeneration ; Hemorrhage ; Humans ; Membranes ; Periodontal Pocket ; Periodontitis ; Transplantation, Heterologous

PURPOSE: The calcineurin inhibitors, tacrolimus and cyclosporine, have been used as primary immunosuppressant in renal transplantation. Tacrolimus has been shown to be an effective alternative to cyclosporine for the prevention of acute rejection but the two drugs are different in side-effect profile. This retrospective study compares the efficacy and safety of tacrolimus-based versus cyclosporine-based immunosuppression in patients receiving kidney transplantation. METHODS: There were 177 consecutive recipients of kidney graft; 90 received cyclosporine-based immunosuppression therapy, and 87 received tacrolimus-based immunosuppression. Graft and patient survival rate, incidence of acute rejection and side effects were compared. RESULTS: The 3-year graft survival rate of cyclosporine and tacrolimus was similar (93.0% vs. 91.4%). The incidence of acute rejection was significantly less in the tacrolimus group compared with the cyclosporine group (10.3% vs. 31.1%, P<0.05). Incidence of impaired renal function, gastrointestinal disorder, tremor, hypertension and hyperkalemia were comparable in both treatment groups. Higher incidence of posttransplant diabetes, allopecia, abdominal pain and headache was reported in the tacrolimus group, whereas that of hypercholesterolmeia, hirsuitism, and gum hyperplasia was more frequent with cyclosporine group. CONCLUSION: Tacrolimus is as effective as cyclosporine in patient and graft survival in kidney transplantation. Due to different side-effect profiles, it is needed to develop individualized immunosuppressive strategies in renal transplant recipients.
Abdominal Pain ; Calcineurin ; Cyclosporine* ; Gingiva ; Graft Survival ; Headache ; Humans ; Hyperkalemia ; Hyperplasia ; Hypertension ; Immunosuppression ; Incidence ; Kidney Transplantation* ; Kidney* ; Retrospective Studies ; Survival Rate ; Tacrolimus* ; Transplantation ; Transplants ; Tremor

PURPOSE: Tacrolimus (FK-506) represents a major advance in the prevention of rejection following solid organ transplantation. Previous clinical trials in Japan, Europe, and the US suggest that tacrolimus is an effective primary immunosuppressive agent in kidney transplantation. This prospective, non-randomized single center study was done to confirmed the efficacy of tacrolimus in kidney transplantation. METHODS: A total of 50 renal transplant recipients who followed-up at least one year after transplantation was included in this study. Thirty six cases (72%) recived triple drug therapy consists of tacrolimus, mycophenolate mofetil (MMF), and low dose steroid. RESULTS: The overall incidence of acute rejection was 10%, all episodes of rejection were treated effectively with steroid pulse therapy. The incidence of treatment failure was six percent. One and two year graft survival were 98% and 96%, respectively. Adverse effects of tacrolimus therapy included tremor of the hand (56%), diarrhea (34%), alopecia (26%), hyperkalemia (22%), nephrotoxicity (18%), post transplant diabetes mellitus (14%), hypertension (14%), and hypercholesterolemia (10%). However, the incidence of gum hypertrophy and hirsutism were 6% and 2%, respectively. CONCLUSION: This short-term study indicates that tacrolimus appears to provide safe and effective primary immunosuppression in kidney transplantation.
Alopecia ; Diabetes Mellitus ; Diarrhea ; Drug Therapy ; Europe ; Gingiva ; Graft Survival ; Hand ; Hirsutism ; Hypercholesterolemia ; Hyperkalemia ; Hypertension ; Hypertrophy ; Immunosuppression* ; Incidence ; Japan ; Kidney Transplantation* ; Organ Transplantation ; Prospective Studies ; Tacrolimus* ; Transplantation ; Transplants ; Treatment Failure ; Tremor

Adhesives ; Burns ; Calcium Chloride ; Cicatrix ; Cicatrix, Hypertrophic ; Collagen ; Factor XIII ; Fibrin Tissue Adhesive ; Fibrin ; Fibrinogen ; Follow-Up Studies ; Gingiva ; Hemorrhage ; Humans ; Mouth ; Nose ; Polymers ; Skin Transplantation ; Skin ; Surgery, Oral ; Sutures ; Thrombin ; Tissue Donors ; Transplants ; Wound Healing

We report a case of 13 years old male patient. He was diagnosed as glycogen storage disease Ib at 6 month age, and received cadaver donor liver transplantation at 2 years and 4 months. He underwent immunosuppression for 9 years with several immunosuppressants including tacrolimus. Then he visited hospital for gum swelling and showed multiple malignancy suspicious lesions at nasal cavity, maxilla, mandibula, frontal bone, temporal bone, C1 and C2 spines, and several submandibular lymph nodes at radiologic study. Biopsy was done at oral cavity lesion, and histologically diagnosed as diffuse large B-cell lymphoma. The tissue specimen showed positivity in Epstein-Barr virus polymerase chain reaction (PCR). After diagnosis, the patient stopped all immunosuppressive agents and received 9 cycles of CHOP (cyclophosphamide, adriamycin, vincristine and prenisolone) chemotherapy for 8 months, then the patient achieved radiologic remission state, and being well without any signs of recurrence for two years of follow up.
Biopsy ; Cadaver ; Child ; Doxorubicin ; Follow-Up Studies ; Frontal Bone ; Gingiva ; Glycogen Storage Disease ; Glycogen Storage Disease Type I ; Herpesvirus 4, Human ; Humans ; Immunosuppression ; Immunosuppressive Agents ; Liver ; Liver Transplantation ; Lymph Nodes ; Lymphoma ; Lymphoma, B-Cell ; Male ; Maxilla ; Mouth ; Nasal Cavity ; Polymerase Chain Reaction ; Recurrence ; Spine ; Tacrolimus ; Temporal Bone ; Tissue Donors ; Transplants ; Vincristine